The longest life expectancy makes hemophiliacs susceptible to diseases not related to haemophilia and...
Read More
Gene therapy has the potential to revolutionise treatment for patients with haemophilia and is...
In recent years there have been important developments regarding the availability of highly innovative...
Real-life experience in switching to new extended half-life products at European haemophilia centres
The concept of replacement therapy in haemophilia is changing significantly thanks to the switch...
Abstract BACKGROUND: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and...
INTRODUCTION: Haemophilia A is a chronic disease requiring frequent intravenous infusions of recombinant factor...
The development of new biologic agents able to restore thrombin generation has become the...
Hemophilia is a monogenic disease with robust clinicolaboratory correlations of severity. These attributes coupled...
Several new therapies for hemophilia have emerged in recent years. These strategies range from...
Hemorrhage causes significant morbidity and mortality in people aged <65 years. A lyophilized platelet-derived...